Brief: Phio Pharmaceuticals Announces New Clinical Program To Study Ph-762 For The Treatment Of Cutaneous Squamous Cell Carcinoma
21/12/2022 21:19
Dec 21 (Reuters) - Phio Pharmaceuticals Corp PHIO.O :
* PHIO PHARMACEUTICALS ANNOUNCES NEW CLINICAL PROGRAM TO
STUDY
PH-762 FOR THE TREATMENT OF CUTANEOUS SQUAMOUS CELL CARCINOMA
* PHIO PHARMACEUTICALS CORP- EXPECTS TO COMMENCE A US PHASE
1B
CLINICAL TRIAL EARLY IN 2ND HALF OF 2023
* PHIO PHARMACEUTICALS CORP- EXPECTS TO FILE AN IND IN US IN
FIRST
HALF OF 2023 FOR A PHASE 1B CLINICAL TRIAL OF ITS INTASYL™
COMPOUND, PH-762
Source text for Eikon: ID:nPn5shFzma
Further company coverage: PHIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Phio Pharmaceuticals
See all newsPhio Pharmaceuticals Q1 net loss widens on higher R&D costs
Brief: Phio Pharmaceuticals Corp - Enters At The Market Offering Agreement With H.C. Wainwright On April 8, 2026
Brief: Phio Pharmaceuticals Corp Announces Key Tumor Response Data From PH-762 Trial
Brief: Phio Pharmaceuticals Corp To Begin Toxicology Study For Ph-762 Before Human Trials - SEC Filing
Brief: Phio Pharmaceuticals Corp Files For Offering Of Up To 11.8 Million Common Shares By The Selling Stockholders - SEC Filing